Top Clinical Chemistry Researcher Warns of Faulty Antibodies Infiltrating US, European Markets | GenomeWeb

Antibody quality has long loomed as a significant concern for proteomics research, with much discussion in the field of what validation steps are needed and what data vendors should provide to ensure the performance of a given affinity agent.

According to Nader Rifai, director of clinical chemistry at Children's Hospital Boston and the editor-in-chief of the journal Clinical Chemistry, these concerns have recently taken on a new urgency due to the appearance on the market of a large number of faulty antibodies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.